- Home
- WLYB vs VCEL Comparison
WLYB vs VCEL Comparison
Compare WLYB & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- VCEL
- Stock Information
- Founded
- WLYB 1807
- VCEL 1989
- Country
- WLYB United States
- VCEL United States
- Employees
- WLYB N/A
- VCEL N/A
- Industry
- WLYB Books
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WLYB Consumer Discretionary
- VCEL Health Care
- Exchange
- WLYB Nasdaq
- VCEL Nasdaq
- Market Cap
- WLYB 2.3B
- VCEL 2.1B
- IPO Year
- WLYB N/A
- VCEL 1997
- Fundamental
- Price
- WLYB $44.00
- VCEL $41.73
- Analyst Decision
- WLYB
- VCEL Strong Buy
- Analyst Count
- WLYB 0
- VCEL 8
- Target Price
- WLYB N/A
- VCEL $61.75
- AVG Volume (30 Days)
- WLYB 199.0
- VCEL 517.5K
- Earning Date
- WLYB 06-12-2025
- VCEL 05-08-2025
- Dividend Yield
- WLYB 3.21%
- VCEL N/A
- EPS Growth
- WLYB N/A
- VCEL 521.85
- EPS
- WLYB 0.75
- VCEL 0.05
- Revenue
- WLYB $1,703,491,000.00
- VCEL $238,541,000.00
- Revenue This Year
- WLYB N/A
- VCEL $23.23
- Revenue Next Year
- WLYB $1.13
- VCEL $24.41
- P/E Ratio
- WLYB $58.26
- VCEL $800.69
- Revenue Growth
- WLYB N/A
- VCEL 14.80
- 52 Week Low
- WLYB $35.68
- VCEL $37.39
- 52 Week High
- WLYB $52.90
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- WLYB 65.28
- VCEL 51.56
- Support Level
- WLYB $39.54
- VCEL $37.48
- Resistance Level
- WLYB $44.15
- VCEL $39.42
- Average True Range (ATR)
- WLYB 0.01
- VCEL 1.84
- MACD
- WLYB 0.11
- VCEL 0.57
- Stochastic Oscillator
- WLYB 86.96
- VCEL 77.71
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.